Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome

Andrology

Volumn 1, Issue 4, 2013, Pages 570-575

  Rodriguez Tolra J ^a   Torremade J ^a   di Gregorio, S ^b   del Rio, L ^b   Franco, E ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CETIR Centre Medic   (Spain)

Author keywords

Hypogonadism; Sex hormones; Testosterone; Treatment

Indexed keywords

SEX HORMONE BINDING PROTEIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; BONE DENSITY; CLINICAL CHEMISTRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GYNECOMASTIA; HIP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LUMBAR SPINE; MALE; OPEN STUDY; PRIORITY JOURNAL; RATING SCALE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84879535214     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/j.2047-2927.2013.00090.x     Document Type: Article

References (31)

1. Abu EO, Horner A, Kusec V, Triffitt JT & Compston JE. (1997) The localization of androgen receptors in human bone. J Clin Endocrinol Metab 82, 3493-3497.
2. Allan CA, Strauss BJ, Burger HG, Forbes EA & McLachlan RI. (2008) Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 93, 139-146.
3. Amin S, Zhang Y, Felson DT, Sawin CT, Hannan MT & Wilson PW. (2006) Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 119, 426-433.
4. Aminorroaya A, Kelleher S, Conway AJ, Ly LP & Handelsman DJ. (2005) Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 152, 881-886.
5. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD & Matsumoto AM. (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89, 503-510.
6. Behre HM, Kliesch S, Leifke E, Link TM & Nieschlag E. (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82, 2386-2390.
7. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP & Lee M. (2005) Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90, 678-688.
8. Bord S, Horner A, Beavan S & Compston J. (2001) Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab 86, 2309-2314.
9. Cauley JA, Ewing SK, Taylor BC, Fink HA, Ensrud KE & Bauer DC. (2010) Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density-the osteoporotic fractures in men study. J Clin Endocrinol Metab 95, 4314-4323.
10. Dean JD, Carnegie C, Rodzvilla J & Smith T. (2004) Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol 6(Suppl.), S22-S29.
11. Emaus N, Berntsen GK, Joakimsen R & Fonnebo V. (2006) Longitudinal changes in forearm bone mineral density in women and men aged 45-84 years: the Tromso Study, a population-based study. Am J Epidemiol 163, 441-449.
12. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB & Coviello AD. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87, 589-598.
13. Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC & Cauley JA. (2006) Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91, 3908-3915.
14. Guo CY, Jones TH & Eastell R. (1997) Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J Clin Endocrinol Metab 82, 658-665.
15. Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA & Wilson PW. (2000) Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 15, 710-720.
16. Heinemann LA, Saad F, Heinemann K & Thai DM. (2004) Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 7, 211-218.
17. Kenny AM, Prestwood KM, Gruman CA, Marcello KM & Raisz LG. (2001) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 56, M266-M272.
18. Khera M, Miner M, Bhattacharya R, Blick G, Kushner H & Nguyen D. (2010) Testosterone supplementation significantly improves depression symptoms in hypogonadal men enrolled in the TESTIM registry in the US (TRIUS). J Urol 183, e578.
19. Khosla S, Melton LJ III & Riggs BL. (2002) Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 87, 1443-1450.
20. Lorentzon M, Swanson C, Andersson N, Mellstrom D & Ohlsson C. (2005) Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res 20, 1334-1341.
21. McNicholas TA, Dean JD, Mulder H, Carnegie C & Jones NA. (2003) A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 91, 69-74.
22. Mellstrom D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M & Mallmin H. (2006) Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 21, 529-535.
23. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P & McCready D. (2000) Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49, 1239-1242.
24. Smith KW, Feldman HA & McKinlay JB. (2000) Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 53, 703-711.
25. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L & Holmes JH. (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84, 1966-1972.
26. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T & Bachand R. (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88, 2673-2681.
27. Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F & Duboeuf F. (2001) Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 86, 192-199.
28. Tuck SP, Scane AC, Fraser WD, Diver MJ, Eastell R & Francis RM. (2008) Sex steroids and bone turnover markers in men with symptomatic vertebral fractures. Bone 43, 999-1005.
29. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ & Cunningham G. (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85, 2839-2853.
30. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ & Cunningham G. (2001) Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 54, 739-750.
31. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM & Snyder PJ. (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89, 2085-2098.